The immunology of atherosclerosis

Anton Gisterå,Göran K. Hansson
DOI: https://doi.org/10.1038/nrneph.2017.51
IF: 42.439
2017-04-10
Nature Reviews Nephrology
Abstract:Key PointsAtherosclerotic cardiovascular disease is the leading cause of death worldwide; the disease process is accelerated in patients with chronic kidney diseaseHypercholesterolemia leads to accumulation of plasma LDL in the artery wall; LDL and its components elicit vascular inflammation that drives the build-up of lipid-laden atherosclerotic plaquesSeveral small populations of innate immune cells have important roles at different stages of atherosclerosis development, but macrophages are the main innate immune effector cell type in the plaqueT cells that respond to autoantigenic components of LDL particles orchestrate plaque development; T helper type 1 (TH1) cells promote atherosclerosis, regulatory T cells are protective and TH17 cells promote plaque stabilityMany connections between the immune system and metabolism exist; acute inflammation induces hypertriglyceridemia, whereas chronic inflammation has more complex effectsNovel approaches such as anti-inflammatory therapies, T-cell-based treatments or vaccination against LDL, could potentially reduce cardiovascular inflammation and protect against the development of atherosclerosis
urology & nephrology
What problem does this paper attempt to address?